Intron Biotechnology, Inc.

Intron Biotechnology Co., Ltd

Molgenbio Co. Ltd.

Reyon Pharmaceutical Co., Ltd.

Yeo Joon Yoon

Yeon Hee Ban

Ho Jeong Kwon

Jae Kyung Sohng

Je Won Park

Sung Ryeol Park

Shinde Pramodb

Hyo Jeong Kwon

Eunji Cheong

Jae Jong Kim

Si Kyu Lim

Seung-Woo Cho

Yong Sun Bahn

Jong Seung Lee

Myoung-Chong Song

Jin A Jung

Ji Yoon Beom

Heon-Joo Lee

Provided are preparation and use of novel compounds available as main ingredients of a composition for promoting hair growth, wherein the novel compounds are 9-deoxo-31-O-demethyl-prolyl-FK506, 9-deoxo-36,37-dihydro-FK506, 31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-FK520, 31-O-demethyl-FK520, 9-deoxo-31-O-demethyl-FK520, 9-deoxo-FK523, and 9-deoxo-31-O-demethyl-FK523.

Compounds, compositions containing same, and use thereof for promoting hair growth

The present invention relates to an FK506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-FK506, 31-O-demethyl-FK506, or 9-deoxo-31-O-demethyl-FK506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.

FK506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof

Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes,species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.

[object Object]

The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genusor the genus, and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genusor the genus, the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.

The present invention relates to novel tacrolimus analogs, a composition for the prevention or treatment of neurological diseases or immune hypersensitivity disorders comprising the same, a method for preventing or treating neurological diseases or immune hypersensitivity disorders comprising administering the analogs to a subject, a method for preparing the analogs using an isolated modifiedsp. strain wherein the activity of one or more enzymes selected from the group consisting of TcsA, TcsB, TcsC and TcsD is reduced; and the isolated modifiedsp. strain for prepare the analogs.

Tacrolimus analogues, a neuroprotective composition comprising the same, an immunosuppressive composition comprising the same, a method for preparing the same, and a mutant for producing the same

Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes,&#x3c;i/&#x3e; species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.

Growing community of inventors

Seoul, South Korea

Yeo Joon Yoon